Adaptive reports broader NCCN guidance for residual-disease testing
Adaptive ($ADPT) Biotechnologies said updated National Comprehensive Cancer Network guidance for multiple myeloma gives measurable residual disease testing a dedicated section and names clonoSEQ as a testing option. The update specifies a preferred sensitivity of one cancer cell in one million, with one in 100,000 as a minimum, according to the company’s announcement. The guidance addresses testing during maintenance and later treatment settings, including after CAR-T therapy, and retains flow c
0